keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
WORKSHOP
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Clear
WORKSHOP
search
Streams
Formats
Clear
Morning Session
08:55 - 09:005 mins
Market Authorisation Strategy Part 1: Preparing module 3 of the dossier
Chairperson’s Opening Remarks
09:00 - 10:3090 mins
Market Authorisation Strategy Part 1: Preparing module 3 of the dossier
Target audience: those in late stage clinical trials, planning for MAA/BLA or beginning to think about it. Also useful for others involved in the preparation of clinical trials dossiers at any stage.
- Christopher Bravery, Ph.D. - Principal Consultant, Consulting on Advanced Biologicals
11:00 - 12:3090 mins
Market Authorisation Strategy Part 1: Preparing module 3 of the dossier
Target audience: those in late stage clinical trials, planning for MAA/BLA or beginning to think about it. Also useful for others involved in the preparation of clinical trials dossiers at any stage.
- Christopher Bravery, Ph.D. - Principal Consultant, Consulting on Advanced Biologicals
Afternoon Session
13:25 - 13:305 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Chairperson’s Opening Remarks
- Rob Allen - Principal, Dark Horse Consulting
13:25 - 13:305 mins
Market Authorisation Strategy Part 2: Lessons from the first 22 ATMP submitted to the EMA
Chairperson’s Opening Remarks
13:30 - 14:0030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Novel T Cell and Combination TCRT Approaches
- Arjan Roozen - CTO, Zelluna Immonutherapy, Norway
13:30 - 15:30120 mins
Market Authorisation Strategy Part 2: Lessons from the first 22 ATMP submitted to the EMA
Target audience: regulatory professionals and anyone interested in regulatory strategy and the reasons for success or failure at approval
- Christopher Bravery, Ph.D. - Principal Consultant, Consulting on Advanced Biologicals
14:00 - 14:3030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
CYAD-101: A Non-Gene Edited Allogeneic Approach
- Philippe Parone - Director, Industrialization, Celyad, Belgium
14:30 - 15:0030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Off-the shelf, TCR-transduced Gamma Delta T cells for solid cancers
- Ali Mohamed - VP, CMC, Immatics, USA
15:00 - 15:3030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Virus Specific T Cells as Platform for Solid Tumor Immunotherapy
- Richard Hopkins - Research Director, R&D department, Tessa Therapeutics, Singapore
16:00 - 16:3030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Gamma Delta T cells for the treatment of Cancer
- Sean O'Farrell - Senior Scientist, Process Development & Manufacturing at GammaDelta Therapeutics Limited, Gamma Delta Therapeutics
16:00 - 17:0060 mins
Market Authorisation Strategy Part 2: Lessons from the first 22 ATMP submitted to the EMA
Target audience: regulatory professionals and anyone interested in regulatory strategy and the reasons for success or failure at approval
- Christopher Bravery, Ph.D. - Principal Consultant, Consulting on Advanced Biologicals
16:30 - 17:0030 mins
Clinical and Early Stage CAR T and Cell Therapy Advances – Allogeneic, Solid Tumours, Combination Therapies and Safety Switches
Allogeneic Immunotherapy for Renal Cell Cancer
- Sharon Longhurst - Head of CMC, Immunicum
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams
Formats
Clear